Eliem Therapeutics Ownership 2024 | Who Owns Eliem Therapeutics Now?
Institutional Ownership
180.58%
Insider Ownership
10.38%
Retail Ownership
-90.96%
Institutional Holders
47.00
Eliem Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 113.68% | 2.95% | 31,419,267 | 18,268,418 | 138.91% | 223,390,988 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 14.13% | 0.83% | 3,904,785 | 3,904,785 | 100.00% | 27,763,021 | Jun 30, 2024 |
| SAMSARA BIOCAPITAL, LLC | 11.80% | 4.85% | 3,261,393 | 3,261,393 | 100.00% | 23,188,504 | Jun 30, 2024 |
| JANUS HENDERSON GROUP PLC | 11.77% | 0.01% | 3,253,988 | 3,253,988 | 100.00% | 23,135,855 | Jun 30, 2024 |
| BOXER CAPITAL, LLC | 9.42% | 0.97% | 2,603,190 | 2,603,190 | 100.00% | 18,508,681 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 6.04% | 1.37% | 1,670,661 | 1,670,661 | 100.00% | 11,878,400 | Jun 30, 2024 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2.52% | 0.05% | 696,057 | -115,623 | -14.24% | 4,948,965 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.43% | 0.01% | 670,362 | 670,362 | 100.00% | 4,766,274 | Jun 30, 2024 |
| ALLY BRIDGE GROUP (NY) LLC | 1.81% | 2.12% | 500,000 | 500,000 | 100.00% | 3,555,000 | Jun 30, 2024 |
| BLACKROCK INC. | 1.38% | 0.00% | 381,723 | 351,283 | 1154.02% | 2,714,050 | Jun 30, 2024 |
| VANGUARD GROUP INC | 1.18% | - | 326,381 | 15,895 | 5.12% | 2,320,570 | Jun 30, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.78% | 0.21% | 215,179 | 215,179 | 100.00% | 1,529,923 | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | 0.71% | 0.00% | 196,390 | 196,390 | 100.00% | 1,396,333 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.62% | 0.00% | 171,597 | 104,971 | 157.55% | 1,220,219 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 0.36% | 0.12% | 100,000 | 100,000 | 100.00% | 711,001 | Jun 30, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 0.35% | 0.13% | 97,695 | 97,695 | 100.00% | 694,611 | Jun 30, 2024 |
| STATE STREET CORP | 0.21% | - | 59,007 | 37,307 | 171.92% | 419,540,000 | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.20% | 0.01% | 55,223 | - | - | 392,636 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.17% | 0.00% | 45,677 | 2,209 | 5.08% | 324,763,000 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.13% | 0.00% | 37,000 | 26,383 | 248.50% | 263,070 | Jun 30, 2024 |
Eliem Therapeutics's largest institutional shareholder is RA CAPITAL MANAGEMENT, L.P., holding 113.68% of the company's total share outstanding, currently valued at $223.39M. The top 10 institutional shareholders own together 174.98% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 11.80% | 4.85% | 3,261,393 | 3,261,393 | 100.00% | 23,188,504 | Jun 30, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 113.68% | 2.95% | 31,419,267 | 18,268,418 | 138.91% | 223,390,988 | Jun 30, 2024 |
| ALLY BRIDGE GROUP (NY) LLC | 1.81% | 2.12% | 500,000 | 500,000 | 100.00% | 3,555,000 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 6.04% | 1.37% | 1,670,661 | 1,670,661 | 100.00% | 11,878,400 | Jun 30, 2024 |
| BOXER CAPITAL, LLC | 9.42% | 0.97% | 2,603,190 | 2,603,190 | 100.00% | 18,508,681 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 14.13% | 0.83% | 3,904,785 | 3,904,785 | 100.00% | 27,763,021 | Jun 30, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.78% | 0.21% | 215,179 | 215,179 | 100.00% | 1,529,923 | Jun 30, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 0.35% | 0.13% | 97,695 | 97,695 | 100.00% | 694,611 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 0.36% | 0.12% | 100,000 | 100,000 | 100.00% | 711,001 | Jun 30, 2024 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2.52% | 0.05% | 696,057 | -115,623 | -14.24% | 4,948,965 | Jun 30, 2024 |
| JANUS HENDERSON GROUP PLC | 11.77% | 0.01% | 3,253,988 | 3,253,988 | 100.00% | 23,135,855 | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.20% | 0.01% | 55,223 | - | - | 392,636 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.43% | 0.01% | 670,362 | 670,362 | 100.00% | 4,766,274 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.11% | 0.01% | 30,710 | 30,710 | 100.00% | 218,348 | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | 0.71% | 0.00% | 196,390 | 196,390 | 100.00% | 1,396,333 | Jun 30, 2024 |
| POLAR ASSET MANAGEMENT PARTNERS INC. | 0.04% | 0.00% | 10,781 | 10,781 | 100.00% | 76,653 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.08% | 0.00% | 22,192 | 22,192 | 100.00% | 157,785 | Jun 30, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.04% | 0.00% | 10,619 | 10,619 | 100.00% | 75,501 | Jun 30, 2024 |
| MAN GROUP PLC | 0.12% | 0.00% | 33,567 | 33,567 | 100.00% | 238,661 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.13% | 0.00% | 37,000 | 26,383 | 248.50% | 263,070 | Jun 30, 2024 |
The largest Eliem Therapeutics shareholder by % of total assets is SAMSARA BIOCAPITAL, LLC. The company owns 3.26M shares of Eliem Therapeutics (ELYM), representing 4.85% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 113.68% | 2.95% | 31,419,267 | 18,268,418 | 138.91% | 223,390,988 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 14.13% | 0.83% | 3,904,785 | 3,904,785 | 100.00% | 27,763,021 | Jun 30, 2024 |
| SAMSARA BIOCAPITAL, LLC | 11.80% | 4.85% | 3,261,393 | 3,261,393 | 100.00% | 23,188,504 | Jun 30, 2024 |
| JANUS HENDERSON GROUP PLC | 11.77% | 0.01% | 3,253,988 | 3,253,988 | 100.00% | 23,135,855 | Jun 30, 2024 |
| BOXER CAPITAL, LLC | 9.42% | 0.97% | 2,603,190 | 2,603,190 | 100.00% | 18,508,681 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 6.04% | 1.37% | 1,670,661 | 1,670,661 | 100.00% | 11,878,400 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.43% | 0.01% | 670,362 | 670,362 | 100.00% | 4,766,274 | Jun 30, 2024 |
| ALLY BRIDGE GROUP (NY) LLC | 1.81% | 2.12% | 500,000 | 500,000 | 100.00% | 3,555,000 | Jun 30, 2024 |
| BLACKROCK INC. | 1.38% | 0.00% | 381,723 | 351,283 | 1154.02% | 2,714,050 | Jun 30, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.78% | 0.21% | 215,179 | 215,179 | 100.00% | 1,529,923 | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | 0.71% | 0.00% | 196,390 | 196,390 | 100.00% | 1,396,333 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.62% | 0.00% | 171,597 | 104,971 | 157.55% | 1,220,219 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 0.36% | 0.12% | 100,000 | 100,000 | 100.00% | 711,001 | Jun 30, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 0.35% | 0.13% | 97,695 | 97,695 | 100.00% | 694,611 | Jun 30, 2024 |
| STATE STREET CORP | 0.21% | - | 59,007 | 37,307 | 171.92% | 419,540,000 | Jun 30, 2024 |
| MAN GROUP PLC | 0.12% | 0.00% | 33,567 | 33,567 | 100.00% | 238,661 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.11% | 0.01% | 30,710 | 30,710 | 100.00% | 218,348 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.13% | 0.00% | 37,000 | 26,383 | 248.50% | 263,070 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.08% | 0.00% | 22,192 | 22,192 | 100.00% | 157,785 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.07% | - | 18,845 | 18,845 | 100.00% | 133,988 | Jun 30, 2024 |
As of Jun 30 2024, Eliem Therapeutics's largest institutional buyer is RA CAPITAL MANAGEMENT, L.P.. The company purchased 18.27M stocks of ELYM, valued at $223.39M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | - | - | - | -2,193,742 | -100.00% | - | Jun 30, 2024 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2.52% | 0.05% | 696,057 | -115,623 | -14.24% | 4,948,965 | Jun 30, 2024 |
| ATOM INVESTORS LP | - | - | - | -78,276 | -100.00% | - | Jun 30, 2024 |
| TUDOR INVESTMENT CORP ET AL | - | - | - | -29,466 | -100.00% | - | Jun 30, 2024 |
| CHICAGO PARTNERS INVESTMENT GROUP LLC | - | - | - | -12,104 | -100.00% | - | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.04% | - | 11,397 | -8,709 | -43.32% | 81,033 | Jun 30, 2024 |
| UBS GROUP AG | 0.01% | - | 2,218 | -3,707 | -62.57% | 15,770 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -981 | -100.00% | - | Jun 30, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.01% | 0.00% | 3,020 | -586 | -16.25% | 21,472 | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.20% | 0.01% | 55,223 | - | - | 392,636 | Jun 30, 2024 |
| ADVISOR GROUP HOLDINGS, INC. | 0.03% | 0.00% | 8,333 | - | - | 21,665 | Jun 30, 2024 |
| AMALGAMATED BANK | 0.00% | - | 252 | 252 | 100.00% | 2,000 | Jun 30, 2024 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 0.00% | - | 528 | 528 | 100.00% | 3,754 | Jun 30, 2024 |
| LEGAL & GENERAL GROUP PLC | 0.00% | - | 631 | 631 | 100.00% | 4,518 | Jun 30, 2024 |
| ROYAL BANK OF CANADA | 0.00% | - | 686 | 686 | 100.00% | 5,000 | Jun 30, 2024 |
| AMERITAS INVESTMENT PARTNERS, INC. | 0.00% | 0.00% | 714 | 714 | 100.00% | 5,077 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.17% | 0.00% | 45,677 | 2,209 | 5.08% | 324,763,000 | Jun 30, 2024 |
| BARCLAYS PLC | 0.01% | - | 2,543 | 2,543 | 100.00% | 18,000 | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | 0.01% | - | 3,149 | 3,099 | 6198.00% | 22,389 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.01% | - | 3,104 | 3,104 | 100.00% | 22,069 | Jun 30, 2024 |
As of Jun 30 2024, Eliem Therapeutics's biggest institutional seller is BML CAPITAL MANAGEMENT, LLC. The company sold -2.19M shares of ELYM, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| DEEP TRACK CAPITAL, LP | 14.13% | 0.83% | 3,904,785 | 3,904,785 | 100.00% | 27,763,021 | Jun 30, 2024 |
| SAMSARA BIOCAPITAL, LLC | 11.80% | 4.85% | 3,261,393 | 3,261,393 | 100.00% | 23,188,504 | Jun 30, 2024 |
| JANUS HENDERSON GROUP PLC | 11.77% | 0.01% | 3,253,988 | 3,253,988 | 100.00% | 23,135,855 | Jun 30, 2024 |
| BOXER CAPITAL, LLC | 9.42% | 0.97% | 2,603,190 | 2,603,190 | 100.00% | 18,508,681 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 6.04% | 1.37% | 1,670,661 | 1,670,661 | 100.00% | 11,878,400 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.43% | 0.01% | 670,362 | 670,362 | 100.00% | 4,766,274 | Jun 30, 2024 |
| ALLY BRIDGE GROUP (NY) LLC | 1.81% | 2.12% | 500,000 | 500,000 | 100.00% | 3,555,000 | Jun 30, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.78% | 0.21% | 215,179 | 215,179 | 100.00% | 1,529,923 | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | 0.71% | 0.00% | 196,390 | 196,390 | 100.00% | 1,396,333 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 0.36% | 0.12% | 100,000 | 100,000 | 100.00% | 711,001 | Jun 30, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 0.35% | 0.13% | 97,695 | 97,695 | 100.00% | 694,611 | Jun 30, 2024 |
| MAN GROUP PLC | 0.12% | 0.00% | 33,567 | 33,567 | 100.00% | 238,661 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.11% | 0.01% | 30,710 | 30,710 | 100.00% | 218,348 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.08% | 0.00% | 22,192 | 22,192 | 100.00% | 157,785 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.07% | - | 18,845 | 18,845 | 100.00% | 133,988 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.06% | - | 17,128 | 17,128 | 100.00% | 121,780 | Jun 30, 2024 |
| NEW YORK STATE COMMON RETIREMENT FUND | 0.05% | 0.00% | 13,300 | 13,300 | 100.00% | 95,000 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 0.05% | - | 12,560 | 12,560 | 100.00% | 89,302 | Jun 30, 2024 |
| POLAR ASSET MANAGEMENT PARTNERS INC. | 0.04% | 0.00% | 10,781 | 10,781 | 100.00% | 76,653 | Jun 30, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.04% | 0.00% | 10,619 | 10,619 | 100.00% | 75,501 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.03% | 0.00% | 8,233 | 8,233 | 100.00% | 58,529 | Jun 30, 2024 |
| STRS OHIO | 0.02% | 0.00% | 5,300 | 5,300 | 100.00% | 37,683,000 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.01% | 0.00% | 3,918 | 3,918 | 100.00% | 27,896 | Jun 30, 2024 |
| BARCLAYS PLC | 0.01% | - | 2,543 | 2,543 | 100.00% | 18,000 | Jun 30, 2024 |
| AMERITAS INVESTMENT PARTNERS, INC. | 0.00% | 0.00% | 714 | 714 | 100.00% | 5,077 | Jun 30, 2024 |
| ROYAL BANK OF CANADA | 0.00% | - | 686 | 686 | 100.00% | 5,000 | Jun 30, 2024 |
| LEGAL & GENERAL GROUP PLC | 0.00% | - | 631 | 631 | 100.00% | 4,518 | Jun 30, 2024 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 0.00% | - | 528 | 528 | 100.00% | 3,754 | Jun 30, 2024 |
| AMALGAMATED BANK | 0.00% | - | 252 | 252 | 100.00% | 2,000 | Jun 30, 2024 |
Eliem Therapeutics's largest new institutional shareholder by number of shares is DEEP TRACK CAPITAL, LP, purchased 3.90M shares, valued at $27.76M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | - | - | - | -2,193,742 | -100.00% | - | Jun 30, 2024 |
| ATOM INVESTORS LP | - | - | - | -78,276 | -100.00% | - | Jun 30, 2024 |
| TUDOR INVESTMENT CORP ET AL | - | - | - | -29,466 | -100.00% | - | Jun 30, 2024 |
| CHICAGO PARTNERS INVESTMENT GROUP LLC | - | - | - | -12,104 | -100.00% | - | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -981 | -100.00% | - | Jun 30, 2024 |
Eliem Therapeutics's largest sold out institutional shareholder by shares sold is BML CAPITAL MANAGEMENT, LLC, sold -2.19M shares, valued at -, as of undefined.
Eliem Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| BRIDGEWAY FUNDS INC | 0.02% | 53,323 | - | - | Mar 28, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.00% | 1,669 | - | - | Mar 31, 2024 |
| JPMORGAN INSURANCE TRUST | 0.00% | 25,800 | - | - | Mar 31, 2023 |
| QUANTITATIVE MASTER SERIES LLC | 0.00% | 10,890 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.00% | 1,019 | - | - | Mar 31, 2024 |
| Voya INVESTORS TRUST | 0.00% | 40,700 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 308,817 | -119,083 | -27.83% | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 16,001 | - | - | Feb 29, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 61,246 | -236 | -0.38% | Feb 29, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 541 | - | - | Mar 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 3,443 | - | - | Mar 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 2,307 | - | - | Mar 31, 2024 |
| Global X Funds | 0.00% | 1,865 | - | - | Jan 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 349 | - | - | Mar 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 1,300 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 2,676 | - | - | Mar 28, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 65 | - | - | Dec 31, 2023 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 293 | - | - | Feb 29, 2024 |
| ProFunds | 0.00% | 129 | - | - | Mar 31, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 44,248 | - | - | Mar 31, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 20,924 | - | - | Feb 29, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 40 | - | - | Dec 31, 2023 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 2,019 | - | - | Jan 31, 2024 |
| VALIC Co I | 0.00% | 2,236 | - | - | Feb 29, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 480 | - | - | Feb 29, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 200 | - | - | Mar 28, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 921 | - | - | Mar 31, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 41 | - | - | Feb 29, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 7 | - | - | Dec 31, 2023 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 666 | - | - | Jan 31, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 3,894 | - | - | Mar 31, 2024 |
| PROSHARES TRUST | 0.00% | 867 | - | - | Feb 29, 2024 |
| TIAA-CREF FUNDS | 0.00% | 9,707 | - | - | Mar 31, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 5,900 | - | - | Mar 31, 2024 |
| ETF Series Solutions | 0.00% | 50 | - | - | Jan 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 226 | - | - | Feb 29, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 665 | - | - | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 1,137 | - | - | Mar 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 2,922 | - | - | Mar 31, 2024 |
| iSHARES TRUST | 0.00% | 12,634 | -332 | -2.56% | Mar 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 505 | - | - | Dec 31, 2023 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 893 | - | - | Mar 31, 2024 |
| Bridge Builder Trust | 0.00% | 1,560 | - | - | Mar 31, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 830 | - | - | Mar 31, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 925 | - | - | Feb 29, 2024 |
Eliem Therapeutics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 53.32K shares, compromising 0.02% of its total assets.
Eliem Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 47 | 135.00% |
| 31 Mar, 24 | 20 | -9.09% |
| 31 Dec, 23 | 22 | - |
| 30 Sep, 23 | 22 | 4.76% |
| 30 Jun, 23 | 21 | 10.53% |
| 31 Mar, 23 | 19 | -5.00% |
| 31 Dec, 22 | 20 | - |
| 30 Sep, 22 | 20 | -13.04% |
| 30 Jun, 22 | 23 | -46.51% |
| 31 Mar, 22 | 43 | 22.86% |
| 31 Dec, 21 | 35 | 9.38% |
| 30 Sep, 21 | 32 | - |
As of 30 Jun 24, 47 institutions are holding Eliem Therapeutics's shares, representing an increase of 135.00% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 49,910,065 | 196.11% |
| 31 Mar, 24 | 16,855,387 | 0.01% |
| 31 Dec, 23 | 16,853,724 | 0.75% |
| 30 Sep, 23 | 16,728,590 | -0.01% |
| 30 Jun, 23 | 16,730,361 | 0.17% |
| 31 Mar, 23 | 16,702,070 | 0.44% |
| 31 Dec, 22 | 16,628,134 | 12.30% |
| 30 Sep, 22 | 14,807,319 | -2.12% |
| 30 Jun, 22 | 15,127,990 | -13.61% |
| 31 Mar, 22 | 17,511,355 | 0.72% |
| 31 Dec, 21 | 17,385,623 | 0.62% |
| 30 Sep, 21 | 17,279,147 | - |
Eliem Therapeutics (ELYM) has 49.91M shares outstanding as of 30 Jun 24, up 196.11% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 180.58% | 4.88% |
| 31 Mar, 24 | 60.85% | 1.57% |
| 31 Dec, 23 | 62.26% | 1.60% |
| 30 Sep, 23 | 62.33% | 1.56% |
| 30 Jun, 23 | 63.15% | 1.59% |
| 31 Mar, 23 | 63.04% | 1.58% |
| 31 Dec, 22 | 63.20% | 2.00% |
| 30 Sep, 22 | 56.22% | 1.70% |
| 30 Jun, 22 | 57.53% | 1.29% |
| 31 Mar, 22 | 66.74% | 1.52% |
| 31 Dec, 21 | 66.29% | 0.54% |
| 30 Sep, 21 | 110.87% | - |
As of 30 Jun 24, Eliem Therapeutics is held by 180.58% institutional shareholders, representing a 4.88% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 41 | 583.33% |
| 31 Mar, 24 | 6 | -14.29% |
| 31 Dec, 23 | 7 | -12.50% |
| 30 Sep, 23 | 8 | - |
| 30 Jun, 23 | 8 | 14.29% |
| 31 Mar, 23 | 7 | -22.22% |
| 31 Dec, 22 | 9 | 50.00% |
| 30 Sep, 22 | 6 | -50.00% |
| 30 Jun, 22 | 12 | -29.41% |
| 31 Mar, 22 | 17 | -15.00% |
| 31 Dec, 21 | 20 | -37.50% |
| 30 Sep, 21 | 32 | - |
41 institutional shareholders have increased their position in ELYM stock as of 30 Jun 24 compared to 6 in the previous quarter (a 583.33% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 4 | - |
| 31 Mar, 24 | 4 | -42.86% |
| 31 Dec, 23 | 7 | - |
| 30 Sep, 23 | 7 | 16.67% |
| 30 Jun, 23 | 6 | 20.00% |
| 31 Mar, 23 | 5 | -16.67% |
| 31 Dec, 22 | 6 | -25.00% |
| 30 Sep, 22 | 8 | -11.11% |
| 30 Jun, 22 | 9 | -52.63% |
| 31 Mar, 22 | 19 | 171.43% |
| 31 Dec, 21 | 7 | - |
| 30 Sep, 21 | - | - |
4 institutional shareholders have reduced their position in ELYM stock as of 30 Jun 24 compared to 4 in the previous quarter (a 0.00% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 47 | 135.00% | 49,910,065 | 196.11% | 180.58% | 4.88% | 41 | 583.33% | 4 | - |
| 31 Mar, 24 | 20 | -9.09% | 16,855,387 | 0.01% | 60.85% | 1.57% | 6 | -14.29% | 4 | -42.86% |
| 31 Dec, 23 | 22 | - | 16,853,724 | 0.75% | 62.26% | 1.60% | 7 | -12.50% | 7 | - |
| 30 Sep, 23 | 22 | 4.76% | 16,728,590 | -0.01% | 62.33% | 1.56% | 8 | - | 7 | 16.67% |
| 30 Jun, 23 | 21 | 10.53% | 16,730,361 | 0.17% | 63.15% | 1.59% | 8 | 14.29% | 6 | 20.00% |
| 31 Mar, 23 | 19 | -5.00% | 16,702,070 | 0.44% | 63.04% | 1.58% | 7 | -22.22% | 5 | -16.67% |
| 31 Dec, 22 | 20 | - | 16,628,134 | 12.30% | 63.20% | 2.00% | 9 | 50.00% | 6 | -25.00% |
| 30 Sep, 22 | 20 | -13.04% | 14,807,319 | -2.12% | 56.22% | 1.70% | 6 | -50.00% | 8 | -11.11% |
| 30 Jun, 22 | 23 | -46.51% | 15,127,990 | -13.61% | 57.53% | 1.29% | 12 | -29.41% | 9 | -52.63% |
| 31 Mar, 22 | 43 | 22.86% | 17,511,355 | 0.72% | 66.74% | 1.52% | 17 | -15.00% | 19 | 171.43% |
| 31 Dec, 21 | 35 | 9.38% | 17,385,623 | 0.62% | 66.29% | 0.54% | 20 | -37.50% | 7 | - |
| 30 Sep, 21 | 32 | - | 17,279,147 | - | 110.87% | - | 32 | - | - | - |
Eliem Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of Eliem Therapeutics's stock was made by Morisset Valerie on Jul 23 2024, selling 10,201 shares at $7.09 per share (valued at $72.33K). The last insider buy of ELYM was made by RA CAPITAL MANAGEMENT, L.P. on Jul 01 2024, buying 11,949,171 shares at $3.84 per share (worth $45.88M).
Eliem Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 1 | 15 | 6.67% |
| Q2 2024 | 17 | 3 | 566.67% |
| Q1 2024 | 1 | - | - |
| Q3 2023 | 2 | 2 | 100.00% |
| Q2 2023 | 6 | - | - |
| Q1 2023 | 2 | 5 | 40.00% |
| Q4 2022 | 4 | - | - |
| Q2 2022 | 10 | - | - |
| Q1 2022 | 4 | - | - |
| Q3 2021 | 13 | 24 | 54.17% |
1 total buy trades, and 15 total sell trades (buy/sell ratio of 0.07%) were made by Eliem Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | 14 | - |
| Q2 2024 | 2 | 1 | 200.00% |
| Q1 2024 | - | - | - |
| Q3 2023 | - | - | - |
| Q2 2023 | - | - | - |
| Q1 2023 | - | - | - |
| Q4 2022 | - | - | - |
| Q2 2022 | - | - | - |
| Q1 2022 | - | - | - |
| Q3 2021 | 3 | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 14 open market sell trades of Eliem Therapeutics's stocks.
Eliem Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| CYT | Cyteir Therapeutics, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| IPSC | Century Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| CSBR | Champions Oncology, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| HCWB | HCW Biologics Inc. |
| MNOV | MediciNova, Inc. |
| PHVS | Pharvaris N.V. |
| RZLT | Rezolute, Inc. |
| PEPG | PepGen Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| MOLN | Molecular Partners AG |
| PRDS | Pardes Biosciences, Inc. |
| STTK | Shattuck Labs, Inc. |
ELYM Ownership FAQ
Who Owns Eliem Therapeutics?
Eliem Therapeutics is owned by institutional shareholders (180.58%), insiders (10.38%), and public (-90.96%). The largest institutional shareholder of Eliem Therapeutics is RA CAPITAL MANAGEMENT, L.P. (113.68% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.02% of total shares).
Who are the major institutional shareholders of Eliem Therapeutics?
Eliem Therapeutics's major institutional shareholders are RA CAPITAL MANAGEMENT, L.P., DEEP TRACK CAPITAL, LP, SAMSARA BIOCAPITAL, LLC, JANUS HENDERSON GROUP PLC, and BOXER CAPITAL, LLC. The top five shareholders own together 160.80% of the company's share outstanding.
How many Eliem Therapeutics shareholders are there?
As of Jun 2024, there are 47 institutional shareholders of Eliem Therapeutics.
What percentage of Eliem Therapeutics is owned by RA CAPITAL MANAGEMENT, L.P?
RA CAPITAL MANAGEMENT, L.P owns 31.42M shares of Eliem Therapeutics, representing 113.68% of the company's total shares outstanding, valued at $223.39M (as of Jun 2024).
What percentage of Eliem Therapeutics is owned by DEEP TRACK CAPITAL, LP?
As of Jun 2024, DEEP TRACK CAPITAL, LP holds 3.9M shares of Eliem Therapeutics (ELYM), compromising 14.13% of the company, valued at $27.76M.
What percentage of Eliem Therapeutics is owned by SAMSARA BIOCAPITAL, LLC?
SAMSARA BIOCAPITAL, LLC is the third largest holder of Eliem Therapeutics. The company owns 3.26M of the company's shares outstanding (worth $23.19M).